Skip to content

HYPOChLorous Acid TEsting Studies: Interventional DRAINAGE

HYPOChLorous Acid TEsting Studies: Interventional DRAINAGE - HYPOCLATES:DRAINAGE

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
DRKS
Registry ID
DRKS00038653
Enrollment
300
Registered
2025-12-05
Start date
2025-12-01
Completion date
Unknown
Last updated
2025-12-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

T81.4

Interventions

Group 1: Retrospective analysis of clinical routine data from approximately 150 patients who underwent interventional percutaneous placement of an irrigation drainage (episodic irrigation with isotoni

Sponsors

Universitätsklinikum Heidelberg
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: Patients who underwent interventional percutaneous placement of an irrigation drainage.

Exclusion criteria

Exclusion criteria: Pregnancy, history of organ transplantation, inability to administer antibiotics

Design outcomes

Primary

MeasureTime frame
The primary endpoints are the drainage dwell time and the duration of antibiotic therapy. The decision to remove the drainage or discontinue antibiotic therapy remains with the treating physicians.

Secondary

MeasureTime frame
Secondary endpoints include the length of hospital and intensive care unit stay after drainage placement, hospital readmissions, type of antibiotic therapy, re-operations or re-drainages, mortality and morbidity during the hospital stay (Comprehensive Complication Index), infection parameters during the peri- and post-intervention period, intra- and peri-interventional microbial samples, incidence of multi-resistant pathogens at drainage placement and during drainage therapy, hollow organ perforations, post-interventional bleeding, total days of possible catecholamine therapy, total days of possible mechanical ventilation therapy, nosocomial infections (urinary tract infections, pneumonias, bacteremias), myocardial infarctions, pulmonary embolisms, strokes, Clostridium difficile-associated diarrhea, as well as analysis of bacteria detected in samples.

Countries

Germany

Contacts

Public ContactJulian-Camill Harnoss

Universitätsklinikum Universitätsklinikum Heidelberg Klinik für Allgemein-, Viszeral- und Transplantationschirurgie Heidelberg

Julian-Camill.Harnoss@med.uni-heidelberg.de+49 6221 56 6110

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Jul 31, 2026